Bruker, CovalX Combine Technologies for MALDI MS-based Research | GenomeWeb

NEW YORK (GenomeWeb News) – CovalX and Bruker's Daltonics division today announced an agreement to combine their technologies to support research into protein interactions and macromolecular characterization.

The deal will provide customers access to CovalX's High-Mass systems with Bruker Daltonics' MALDI mass spectrometers, a combination of technologies that the two firms said will result in "significantly improved detection capabilities in the 150-2,000 kDa range."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.